Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...

After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a pair of HIV prevention pills.

Jan 11 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory ...

Mark S. King’s January 10 blog post on his award-winning "My Fabulous Disease" site made me aware of a new, and troubling, ...

(Reuters) - Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention ...

Gilead started life as a start-up focused on antivirals and, less than 40 years later, is firmly established as a top 20 pharmaceutical company, by market capitalisation. Rumours emerged four ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gilead Sciences (GILD – Research Report) and ...

Gilead is mounting a challenge against GlaxoSmithKline’s HIV drug, Tivicay, with its rival integrase inhibitor bictegravir. At the same time, GSK’s ViiV HIV unit hit back with data of its own ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Lyell Immunopharma (LYEL – Research Report) ...

Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This collaboration aims to develop treatments for patients suffering from inflammatory ...